AFT introduces Novatear+Omega-3 eye drop in Australia

ASX-listed AFT Pharmaceuticals has expanded its therapeutics range with a new dry eye therapy containing Omega-3.

The company has introduced NovaTears +Omega-3, which is now available in addition to the existing Pharmaceutical Benefits Scheme-listed NovaTears. German firm Novaliq manufactures the therapies.

Click here for more information

Start typing and press Enter to search